TLDR:
– Zynext Ventures, the VC arm of Zydus Lifesciences, has invested in Promaxo, a developer of portable low-field MRI systems and minimally invasive robotics.
– Promaxo’s technology aims to revolutionize patient care by enabling point-of-care imaging and intervention.
Zynext Ventures, the VC arm of Zydus Lifesciences, has announced its investment in Promaxo, a US-based developer of portable low-field MRI systems and minimally invasive robotics. Promaxo’s technology is designed to revolutionize patient care by enabling point-of-care imaging and intervention. The portable low-field MRI systems developed by Promaxo have received FDA 510(k) clearance for prostate biopsy and treatment, making them the first of their kind in the USA. These systems have an open and compact design, limited fringe field, and are compatible with robotic procedures, enhancing precision and predictability in prostate interventions. Zydus Lifesciences Ltd.’s Managing Director, Dr. Sharvil Patel, expressed the company’s commitment to supporting innovations that address unmet medical needs through this investment in Promaxo. Promaxo’s Founder and CEO, Dr. Amit Vohra, highlighted the partnership with Zynext Ventures as a means to accelerate the mission of enhancing quality of care and patients’ lives through innovative technology. Zynext Ventures’ Director, Jay Kothari, stated that the investment in Promaxo aligns with Zynext’s goal of supporting disruptive healthcare solutions that improve patient outcomes. The investment comes at a significant time, as the National Cancer Institute reports a high number of men living with prostate cancer in the US and a growing market for prostate biopsies and treatments. Promaxo is also looking to expand into other areas such as female pelvic, kidney, breast, and orthopedic imaging. Overall, the investment in Promaxo represents a strategic move by Zynext Ventures to support cutting-edge healthcare technologies that address critical healthcare needs and improve patient outcomes.
